Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We formed the GEnetics of Nephropathy-an International Effort (GENIE) consortium to examine previously reported genetic associations with diabetic nephropathy (DN) in type 1 diabetes. GENIE consists of 6,366 similarly ascertained participants of European ancestry with type 1 diabetes, with and without DN, from the All Ireland-Warren 3-Genetics of Kidneys in Diabetes U.K. and Republic of Ireland (U.K.-R.O.I.) collection and the Finnish Diabetic Nephropathy Study (FinnDiane), combined with reanalyzed data from the Genetics of Kidneys in Diabetes U.S. Study (U.S. GoKinD). We found little evidence for the association of the EPO promoter polymorphism, rs161740, with the combined phenotype of proliferative retinopathy and end-stage renal disease in U.K.-R.O.I. (odds ratio [OR] 1.14, P = 0.19) or FinnDiane (OR 1.06, P = 0.60). However, a fixed-effects meta-analysis that included the previously reported cohorts retained a genome-wide significant association with that phenotype (OR 1.31, P = 2 × 10(-9)). An expanded investigation of the ELMO1 locus and genetic regions reported to be associated with DN in the U.S. GoKinD yielded only nominal statistical significance for these loci. Finally, top candidates identified in a recent meta-analysis failed to reach genome-wide significance. In conclusion, we were unable to replicate most of the previously reported genetic associations for DN, and significance for the EPO promoter association was attenuated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402313 | PMC |
| http://dx.doi.org/10.2337/db11-0751 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ELAVL1-stabilized USP22 promotes diabetic nephropathy progression via mediating podocyte injury and death by triggering ACSL4 deubiquitination.
Transpl Immunol
September 2025
Department of Endocrine, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Background: Diabetic nephropathy (DN) represents approximately 50 % of all chronic kidney disease cases. Given the established involvement of USP22 in DN progression, this study investigated its underlying regulatory mechanisms.
Methods: Mouse podocytes were treated with high glucose (HG), and a diabetic mouse model was established.
Histone methylation of kidney disease: fact or fantasy?
Ren Fail
December 2025
Department of Nephrology, The First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, China.
Histone methylation (HMT), the enzymatic addition of methyl groups to specific histone residues by histone methyltransferases, constitutes a key regulatory mechanism in gene expression and post-translational modulation. Although studies have explored HMT's role in oncogenesis and other organ-specific disorders, HMT is now implicated in the pathogenesis of kidney diseases. A broad spectrum of experimental models, including both and systems, has demonstrated the involvement of HMT alterations in diverse renal pathologies such as acute kidney injury, renal fibrosis, diabetic nephropathy, lupus nephritis, polycystic kidney disease, kidney stones, renal cell carcinoma, and immunoglobulin A nephropathy.
View Article and Find Full Text PDFCRISPR and gene editing for kidney diseases: where are we?
Clin Kidney J
September 2025
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Genome editing technologies, particularly clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, have transformed biomedical research by enabling precise genetic modifications. Due to its efficiency, cost-effectiveness and versatility, CRISPR has been widely applied across various stages of research, from fundamental biological investigations in preclinical models to potential therapeutic interventions. In nephrology, CRISPR represents a groundbreaking tool for elucidating the molecular mechanisms underlying kidney diseases and developing innovative therapeutic approaches.
View Article and Find Full Text PDFOrganoids: their emerging essential role in pathological mechanisms and drug discovery of diabetes and its complications.
Front Pharmacol
August 2025
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China.
Diabetes mellitus is a metabolic disease with a high global prevalence, which affects blood vessels throughout the entire body. As the disease progresses, it often leads to complications, including diabetic retinopathy and nephropathy. Currently, in addition to traditional cellular and animal models, more and more organoid models have been used in the study of diabetes and have broad application prospects in the field of pharmacological research.
View Article and Find Full Text PDFRenoprotective effects of GHRH agonist MR409 is associated with reduced oxidative stress and ferroptosis in diabetic mice.
Front Pharmacol
August 2025
Shenyang Key Laboratory of Vascular Biology, Science and Experimental Research Center of Shenyang Medical College, Shenyang, China.
MR409, a synthetic growth hormone-releasing hormone (GHRH) analogue, has demonstrated therapeutic potential in enhancing islet cell transplantation efficacy in diabetes mice and exerts beneficial effects on cardiovascular diseases. The present study investigated the renoprotective effects of MR409 on db/db and streptozotocin (STZ)-induced diabetic mice, focusing on its role in modulating oxidative stress and ferroptosis. db/db or STZ mice combined with high fat diet were used to establish the type 2 diabetic models.
View Article and Find Full Text PDF